Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 404-310-0 | CAS number: 10591-85-2 PERKACIT TBZTD; PERKACIT TBZTD PDR; PERKACIT TBZTD PDR-D; TBZD
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Short description of key information on bioaccumulation potential result:
Based on its high molecular weight, low water solubility and other physico-chemical parameters the bioavailability of TBzTD is expected to be low. Absorption via the oral, inhaltory and dermal route is estimated to be about 10% each.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
Additional information
Oral
The octanol/water partition coefficient of TBzTD, being 3.4-3.7, is favourable for absorption. However, the water solubility of TBzTD is very low (below 0.01 mg/L at 20°C). In general, a compound needs to be dissolved before it can be taken up from the gastro-intestinal tract after oral administration (1). The absorption will furthermore be lowered by the relatively large molecular weight of the compound (MW>500), limiting the passage through biological membranes. Overall, it is expected that TBzTD will be absorbed to a limited extend in the gastro-intestinal tract. For risk assessment purposes the oral absorption of TBzTD is set at 10%. The results of the toxicity studies do not provide reason to deviate from this proposed oral absorption. After absorption of TBzTD from the gastro-intestinal tract, metabolism may occur in the liver (3). Excretion of TBzTD will mainly occur via faeces, due to the low water solubility and relative high molecular weight of the substance. As a consequence of the relative high molecular weight of TBzTD, excretion in bile is considered not relevant.
Inhalation
The relatively low vapour pressure / high boiling point indicate that the substance will not be available for inhalation as a vapour. In the absence of data on particle size distribution, absorption resulting from exposure via inhalation cannot be excluded, and is therefore assumed to take place. Particles with a size <100 μm have the potential to be inhaled. Particles with a diameter >5 μm will deposit in the nasopharyngeal region and subsequently be coughed or sneezed out of the body or swallowed. Particles below 5 μm might reach the tracheobronchial or pulmonary regions. TBzTD, being a lipophilic substance (log Pow 3.4-3.7) has the potential to be absorbed directly. However, based on its low water solubility (below 0.01 mg/L at 20°C) TBzTD will not dissolve into the mucus lining of the respiratory tract. For risk assessment purposes, the inhalation absorption for TBzTD is set at 10%, based on the low water solubility of TBzTD. Dermal TBzTD being a solid with a relative high molecular weight has no real potential for dermal absorption. Furthermore, its low water solubility does not facilitate dermal absorption. However, the criteria for 10% dermal absorption as given in the TGD (2) (IV1W>500 and log Pow >4) are not met, and therefore 100% dermal absorption of TBzTD should be considered for risk assessment purposes. It is, however, generally accepted that dermal absorption is lower compared to oral absorption. The 100% dermal absorption derived from physical/chemical properties of the substance should therefore be considered as a non-realistic assumption, and for risk assessment purposes a lower dermal absorption of e.g. 10% might be considered more appropriate. Based on the present available data, no additional conclusions can be drawn on the distribution, metabolism and excretion of TBzTD after dermal absorption
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.